1 July 2026 - The July 2026 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The July issue of the Schedule includes has many new/revised listings of note:

• Adrenaline (neffy) - new formulation
• Alectinib hydrochloride (Alecensa) - new indication
• Futibatinib (Lytgobi) - new medicine
• Insulin degludec (Tresiba Penfill) - new medicine
• Osimertinib mesylate (Tagrisso) - new indication
• Pertuzumab (Perjeta) - new indication
• Romidepsin (Romidepsin Reach) - new medicine
• Rozanolixizumab (Rystiggo) - new medicine
• Somapacitan (Sogroya) - new medicine
• Tezepelumab (Tezspire) - new medicine
• Ustekinumab (Wezlana) - new biosimilar medicne

Read Summary of PBS changes